Contracts › 75A50123C00067
75A50123C00067: Bioaegis: Plasma Gelsolin (PGSN), an Abundant, Circulating Protein Modulates Inflammation While Also Enhancing Host Defenses By Stimulating the Uptake and Killing of Pathogens. Clinical Studies Have Consistently Shown Pgsn Is Depleted in Severe I
Awarded to Bioaegis Therapeutics Inc by Office of Assistant Secretary for Preparedness and Response.
$20.0Mobligated
$20.0Mpotential value
31 August 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50123C00067 |
|---|---|
| Awardee | Bioaegis Therapeutics Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | NJ |
| Offers received | 100 |
| Period of performance | 21 September 2023 to 31 August 2027 |
| Potential end | 31 August 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record